{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:46:26Z","timestamp":1757544386696,"version":"3.41.2"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background\/purpose<\/jats:title><jats:p>Despite advances in chronic lymphocytic leukemia treatment, effective therapies for cases with Richter\u2019s transformation (RT) are urgently needed. This study aimed to investigate the use of chimeric antigen receptor (CAR)-T cell infusion for RT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study included RT patients at Beijing Boren Hospital between February 2020 and February 2023. Complete response (CR), partial response (PR), overall response rate (ORR), overall survival (OS), progression free survival (PFS), and adverse events were analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from 16 patients with RT who underwent CAR-T cell therapy [62.5% (10\/16) males and a median age of 59 years (range: 42\u201369 years)] were collected. The 3-month CR rate was 56.3% (9\/16), with an ORR of 68.8% (11\/16). Median follow-up was 19.1 months (4.37-42.48m), the 1-year OS\/PFS were 75.0%\/68.8%, and the 2-year OS\/PFS were 67.5%\/61.1%. Among 11 patients with CR (n=9) and PR (n=2), 1 CR case died of an acute coronary event, 10 patients had no recurrence or progression at a median follow-up of 24.6 months. Five patients who did not respond to CAR-T cell therapy had a median OS of only 6.44 months. Univariate logistic regression analysis showed ECOG score [odds ratio (OR)=0.025, P=0.016] were independently associated with ORR. ECOG (OR=40, P=0.016) were independently associated with OS. The presence of an extramedullary mass larger than 5cm did not show statistical significance for overall survival (OS), although the P value was close to 0.05 (OR=15, P=0.051).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>CAR-T cell therapy showed potential as a treatment for RT. ECOG score may be independently associated with ORR and OS. RT patients may experience prolonged remission and achieve long-term disease control if they attain remission through chimeric antigen receptor T-cell therapy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1591360","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T04:10:36Z","timestamp":1749442236000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Chimeric antigen receptor (CAR)\u00a0-T cell therapy treatment Richter's transformation"],"prefix":"10.3389","volume":"15","author":[{"given":"Shaomei","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peihao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haidi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiling","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuelu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixia","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/PPO.0b013e31826cda2d","article-title":"Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease","volume":"18","author":"Santos","year":"2012","journal-title":"Cancer J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001811","article-title":"Chronic lymphocytic leukemia in China","volume":"135","author":"Gale","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.v94.11","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31931","article-title":"Chronic lymphocytic leukemia (CLL) treatment: So many choices, such great options","volume":"125","author":"Sharma","year":"2019","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-791376","article-title":"Biology and treatment of Richter syndrome","volume":"131","author":"Rossi","year":"2018","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23939","article-title":"Hodgkin transformation of chronic lymphocytic leukemia: Incidence, outcomes, and comparison to de novo Hodgkin lymphoma","volume":"90","author":"Parikh","year":"2015","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0797-x","article-title":"Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials","volume":"35","author":"Al-Sawaf","year":"2021","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.888109","article-title":"Cellular therapy in high-risk relapsed\/refractory chronic lymphocytic leukemia and richter syndrome","volume":"12","author":"Barbanti","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.790004","article-title":"Clonal evolution of high-risk chronic lymphocytic leukemia: A contemporary perspective","volume":"11","author":"Kwok","year":"2021","journal-title":"Front Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005650","article-title":"Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia","volume":"137","author":"Klintman","year":"2021","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"355ra116","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin\u2019s lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061838","article-title":"Cellular therapies in chronic lymphocytic leukemia and richter\u2019s transformation: recent developments in chimeric antigen receptor T-cells, natural killer cells, and allogeneic stem cell transplant","volume":"15","author":"Coombs","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002783","article-title":"Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome","volume":"4","author":"Kittai","year":"2020","journal-title":"Blood Adv"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00033","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy for richter transformation: an international, multicenter, retrospective study","volume":"42","author":"Kittai","year":"2024","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-506741","article-title":"Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell Malignancies relapsed after allogeneic stem cell transplant: a phase 1 study","volume":"122","author":"Cruz","year":"2013","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.v96.12","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am J Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-8051-8_8","article-title":"Richter syndrome","volume":"792","author":"Rossi","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221103820","article-title":"Long-term follow-up and future direction on the management of chronic lymphocytic leukemia\/small lymphocytic leukemia","volume":"28","author":"Hanna","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.025","article-title":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic Malignancies","volume":"146","author":"Freyer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.925985","article-title":"CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments","volume":"13","author":"Jogalekar","year":"2022","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050293","article-title":"CAR T cell therapy for chronic lymphocytic leukemia: successes and shortcomings","volume":"29","author":"Todorovic","year":"2022","journal-title":"Curr Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1285406","article-title":"Broadening the horizon: potential applications of CAR-T cells beyond current indications","volume":"14","author":"Karsten","year":"2023","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"101163","DOI":"10.1016\/j.blre.2023.101163","article-title":"Richter\u2019s transformation: Transforming the clinical landscape","volume":"64","author":"Barrett","year":"2024","journal-title":"Blood Rev"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1591360\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T04:10:36Z","timestamp":1749442236000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1591360\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":30,"alternative-id":["10.3389\/fonc.2025.1591360"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1591360","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"article-number":"1591360"}}